PMC · DOI:10.1002/jcph.70154·January 30, 2026
Addressing a Common Misconception of Simple Additive and Cumulative Drug Inhibition: Multiple Weak Inhibitors of Common Metabolic Pathway Do Not Pose a Strong Interaction Risk!
Daniel Scotcher, Avijit Ghosh, Aleksandra Galetin, Amin Rostami‐Hodjegan
Abstract
Figures2
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmacogenetics and Drug Metabolism · Pharmaceutical studies and practices · Pharmaceutical Practices and Patient Outcomes